Antiviral options for biodefense

被引：4
|
作者：
Byrd, Chelsea M. [1 ]
Grosenbach, Douglas W. [1 ]
Hruby, Dennis E. [1 ]
机构：
[1] SIGA Technol Inc, Corvallis, OR 97333 USA
来源：
CURRENT OPINION IN VIROLOGY | 2013年 / 3卷 / 05期
关键词：
ANTIPOXVIRUS COMPOUND ST-246; IN-VIVO; ARENAVIRUS INHIBITORS; SMALL-MOLECULE; ECZEMA VACCINATUM; SMALLPOX VACCINEE; HUMAN VOLUNTEERS; MONKEYPOX VIRUS; DRUG ST-246; EFFICACY;
D O I：
10.1016/j.coviro.2013.05.020
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
A key to biodefense strategies is an assessment of current therapies available as well as the expedited development of new antiviral therapeutic options. Viruses make up the majority of the National Institute of Allergy and Infectious Diseases (NIAID) Category A Priority Pathogens, agents that are considered to pose the greatest risk to public health and national security, and yet there are currently no approved treatments for most of these viral biodefense threats. A review of the Category A viral biothreat agents and strategies for the development of new therapeutics are presented here.
引用
收藏
页码：537 / 541
页数：5
相关论文
共 50 条
12345